- Home
- BUSE vs VRDN Comparison
BUSE vs VRDN Comparison
Compare BUSE & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- VRDN
- Stock Information
- Founded
- BUSE 1868
- VRDN 2006
- Country
- BUSE United States
- VRDN United States
- Employees
- BUSE N/A
- VRDN N/A
- Industry
- BUSE Major Banks
- VRDN Medical Specialities
- Sector
- BUSE Finance
- VRDN Health Care
- Exchange
- BUSE Nasdaq
- VRDN Nasdaq
- Market Cap
- BUSE 2.1B
- VRDN 2.1B
- IPO Year
- BUSE N/A
- VRDN N/A
- Fundamental
- Price
- BUSE $22.80
- VRDN $27.49
- Analyst Decision
- BUSE Buy
- VRDN Strong Buy
- Analyst Count
- BUSE 7
- VRDN 11
- Target Price
- BUSE $26.57
- VRDN $39.60
- AVG Volume (30 Days)
- BUSE 424.8K
- VRDN 1.8M
- Earning Date
- BUSE 10-28-2025
- VRDN 11-05-2025
- Dividend Yield
- BUSE 4.39%
- VRDN N/A
- EPS Growth
- BUSE N/A
- VRDN N/A
- EPS
- BUSE 1.27
- VRDN N/A
- Revenue
- BUSE $583,913,000.00
- VRDN $70,789,000.00
- Revenue This Year
- BUSE $62.62
- VRDN N/A
- Revenue Next Year
- BUSE $11.33
- VRDN $37,670.06
- P/E Ratio
- BUSE $17.97
- VRDN N/A
- Revenue Growth
- BUSE 33.62
- VRDN 23340.07
- 52 Week Low
- BUSE $18.40
- VRDN $9.90
- 52 Week High
- BUSE $28.30
- VRDN $28.60
- Technical
- Relative Strength Index (RSI)
- BUSE 46.91
- VRDN 73.84
- Support Level
- BUSE $22.13
- VRDN $22.14
- Resistance Level
- BUSE $23.31
- VRDN $24.23
- Average True Range (ATR)
- BUSE 0.53
- VRDN 1.33
- MACD
- BUSE 0.01
- VRDN 0.22
- Stochastic Oscillator
- BUSE 49.32
- VRDN 85.61
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).